Cerebramed Company
CerebraMed develops a technology for drug therapy designed to treat patients by correcting malfunctioning cellular processes. CerebraMed has developed proprietary GSK-3 inhibitors as drug candidates. The company's findings are relevant for the treatment of both Alzheimer's and amyotrophic lateral sclerosis.
Technology:
N/A
Industry:
Personalized Medicine
Headquarters:
Tel Aviv, Israel
Founded Date:
Undisclosed
Employees Number:
Undisclosed
Funding Status:
N/A
Register and Claim Ownership